ArticleOncogene2016
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
272 citing papers in PubMed, 2 syntheses or guidelines pooled it, 439 citations in OpenAlex.
- Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward?Frontiers in immunology · 2025Pooled it
- Prognostic and Clinicopathological Value of ZWINT Expression Levels in Patients with Lung Adenocarcinoma: A Systematic Review and Meta-analysis.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.Experimental hematology & oncology · 2026Review
- Article
- Review
- Targeting galactose metabolic reprogramming overcomes immunotherapy resistance in KRAS-mutant lung adenocarcinoma: Integrative multi-omics and machine learning approaches.Translational oncology · 2026Article
- Integrative transcriptomic and experimental analysis identifies GREM1 as a pro-metastatic mediator in lung adenocarcinoma.Journal of translational medicine · 2026Article
- Construction of a ferroptosis-related prognostic signature and identification ofTranslational cancer research · 2026Article
- Unveiling the prognostic and immunotherapeutic role of Tregs in lung cancer using integrated analysis of single-cell and bulk RNA-sequencing.Oncology letters · 2026Article
- Integrative multi-omics analysis identifies a circadian rhythm-associated gene signature for prognosis and therapeutic stratification in lung adenocarcinoma.Discover oncology · 2026Article
- Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma.Molecular oncology · 2026Article
- E2F-mediated activation of mTORC1 through the ubiquitin-proteasome system promotes lung adenocarcinoma progression.Cell death & disease · 2026Article
- Deciphering microenvironmental heterogeneity by scalable Niche Guided Module Discovery.Communications biology · 2026Article
- Investigation of the Prevalence of Associated Genetic Mutations (Co-Mutations) in Patients with Actionable Driver Mutations in Lung Cancer: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- FOSL1 promotes homologous recombination repair and camptothecin resistance via TCOF1-mediated ribosome biogenesis in non-small cell lung cancer.Translational oncology · 2026Article
- Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets.Journal of translational medicine · 2026Article
- Epithelial plasticity shapes intratumoral heterogeneity and cell lineages in early-stage lung cancer.Science advances · 2026Article
- Charting cell-type-specific positive genetic interaction at single-cell resolution for lung adenocarcinoma.NPJ precision oncology · 2026Article
- Article
- Construction of a Prognostic Model for Lung Adenocarcinoma Based on Necrosis by Sodium Overload-Related Genes and Identification of DENND1C as a New Prognostic Marker.Current issues in molecular biology · 2026Article
212 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that the presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of heterogeneity in KRAS-mutant tumors. To address this, we utilized a large cohort of resected tumors from 442 lung adenocarcinoma patients with data including annotation of prevalent driver mutations (KRAS and EGFR) and tumor suppressor mutations (STK11 and TP53), microarray-based gene expression and clinical covariates, including overall survival (OS). Specifically, we determined impact of STK11 and TP53 mutations on a new KRAS mutation-associated gene expression signature as well as previously defined signatures of tumor cell proliferation and immune surveillance responses. Interestingly, STK11, but not TP53 mutations, were associated with highly elevated expression of KRAS mutation-associated genes. Mutations in TP53 and STK11 also impacted tumor biology regardless of KRAS status, with TP53 strongly associated with enhanced proliferation and STK11 with suppression of immune surveillance. These findings illustrate the remarkably distinct ways through which tumor suppressor mutations may contribute to heterogeneity in KRAS-mutant tumor biology. In addition, these studies point to novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.